Literature DB >> 28567384

Radiosensitization of cancer stem cells in glioblastoma by the simultaneous inhibition of parallel DNA damage response pathways.

Yasunori Fukumoto1.   

Abstract

Entities:  

Year:  2017        PMID： 28567384      PMCID： PMC5440309          DOI： 10.21037/atm.2017.03.39

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  20 in total

Review 1.  The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.

Authors:  Joanne Smith; Lye Mun Tho; Naihan Xu; David A Gillespie
Journal:  Adv Cancer Res       Date:  2010       Impact factor: 6.242

2.  Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells.

Authors:  M Venere; P Hamerlik; Q Wu; R D Rasmussen; L A Song; A Vasanji; N Tenley; W A Flavahan; A B Hjelmeland; J Bartek; J N Rich
Journal:  Cell Death Differ       Date:  2013-10-11       Impact factor: 15.828

3.  Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas.

Authors:  J Bartkova; P Hamerlik; M-T Stockhausen; J Ehrmann; A Hlobilkova; H Laursen; O Kalita; Z Kolar; H S Poulsen; H Broholm; J Lukas; J Bartek
Journal:  Oncogene       Date:  2010-06-28       Impact factor: 9.867

4.  Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.

Authors:  Marcus Eich; Wynand Paul Roos; Teodora Nikolova; Bernd Kaina
Journal:  Mol Cancer Ther       Date:  2013-08-19       Impact factor: 6.261

5.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

6.  CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines.

Authors:  Amy M McCord; Muhammad Jamal; Eli S Williams; Kevin Camphausen; Philip J Tofilon
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

Review 7.  DNA repair pathways as targets for cancer therapy.

Authors:  Thomas Helleday; Eva Petermann; Cecilia Lundin; Ben Hodgson; Ricky A Sharma
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

8.  A restricted cell population propagates glioblastoma growth after chemotherapy.

Authors:  Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

Review 9.  PARP inhibitors in the management of breast cancer: current data and future prospects.

Authors:  Luca Livraghi; Judy E Garber
Journal:  BMC Med       Date:  2015-08-13       Impact factor: 8.775

10.  Selective Inhibition of Parallel DNA Damage Response Pathways Optimizes Radiosensitization of Glioblastoma Stem-like Cells.

Authors:  Shafiq U Ahmed; Ross Carruthers; Lesley Gilmour; Salih Yildirim; Colin Watts; Anthony J Chalmers
Journal:  Cancer Res       Date:  2015-08-17       Impact factor: 12.701
View more
  1 in total

1.  Hyperoxygenation as a Therapeutic Supplement for Treatment of Triple Negative Breast Cancer.

Authors:  Jesse M Mast; Periannan Kuppusamy
Journal:  Front Oncol       Date:  2018-11-20       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.